Variants in clopidogrel-relevant genes and early neurological deterioration in ischemic stroke patients receiving clopidogrel

Xingyang Yi, Qiang Zhou, Yongyin Zhang, Ju Zhou, Jing Lin, Xingyang Yi, Qiang Zhou, Yongyin Zhang, Ju Zhou, Jing Lin

Abstract

Background: Early neurological deterioration (END) is common in acute ischemic stroke (IS). However, the underlying mechanisms for END are unclear. The aim of this study was to evaluate the associations of 16 variants in clopidogrel-relevant genes and interactions among these variants with END in acute IS patients receiving clopidogrel treatment.

Methods: We consecutively enrolled 375 acute IS patients between June 2014 and January 2015. Platelet aggregation was measured on admission and after the 7-10 days of clopidogrel treatment. The 16 variants in clopidogrel-relevant genes were examined using mass spectrometry. The primary outcome was END within the 10 days of admission. Gene-gene interactions were analyzed by generalized multifactor dimensionality reduction (GMDR) methods.

Results: Among the 375 patients, 95 (25.3%) patients developed END within the first 10 days of admission. Among the 16 variants, only CYP2C19*2 (rs4244285) AA/AG was associated with END using single-locus analytical approach. GMDR analysis revealed that there was a synergistic effect of gene-gene interactions among CYP2C19*2 rs4244285, P2Y12 rs16863323, and GPIIIa rs2317676 on the risk for END. The high-risk interactions among the three variants were associated with the higher platelet aggregation and independent predictor for END after adjusting for the covariates (hazard ratio: 2.82; 95% confidence interval: 1.36-7.76; P = 0.003).

Conclusions: END is very common in patients with acute IS. The mechanisms leading to END are most likely multifactorial. Interactions among CYP2C19*2 rs4244285, P2Y12 rs16863323, and GPIIIa rs2317676 may confer a higher risk for END. It was very important to modify clopidogrel therapy for the patients carrying the high-risk interactive genotypes.

Clinical trial registration information: The study described here is registered at http://www.chictr.org/ (unique Identifier: ChiCTR-OCH-14004724). The date of trial registration was May 30, 2014.

Keywords: Clopidogrel; Early neurological deterioration; Genetic polymorphism; Glycoprotein IIIa; Ischemic stroke; Pharmacogenetics; Platelet membrane receptor.

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Probability of Survival Free of END. Kaplan-Maier analysis of cumulative freedom from END associated with high-risk interactive genotype (Figure). END indicates early neurological deterioration

References

    1. GBD 2013 Mortality and Causes of Death Collaborators Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: A systematic analysis for the global burden of disease study 2013. Lancet. 2015;385:117–171. doi: 10.1016/S0140-6736(14)61682-2.
    1. Jiang B, Wang WZ, Chen H, Hong Z, Yang QD, Wu SP, et al. Incidence and trends of stroke and its subtypes in China: results from three large cities. Stroke. 2006;37:63–68. doi: 10.1161/01.STR.0000194955.34820.78.
    1. Yi X, Han Z, Zhou Q, Lin J, Liu P. 20-Hydroxyeicosatetraenoic acid as a predictor of neurological deterioration in acute minor ischemic stroke. Stroke. 2016;47:3045–3047. doi: 10.1161/STROKEAHA.116.015146.
    1. Tei H, Uchiyama S, Ohara K, Kobayashi M, Uchiyama Y, Fukuzawa M. Deteriorating ischemic stroke in 4 clinical categories classified by the Oxfordshire community stroke project. Stroke. 2000;31:2049–2054. doi: 10.1161/01.STR.31.9.2049.
    1. Yi X, Wang C, Liu P, Fu C, Lin J, Chen Y. Antiplatelet drug resistance is associated with early neurological deterioration in acute minor ischemic stroke in the Chinese population. J Neurol. 2016;263:1612–1629. doi: 10.1007/s00415-016-8181-5.
    1. Vahidy FS, Hicks WJ, 2nd, Acosta I, Hallevi H, Peng H, Pandurengan R, et al. Neurofluctuation in patients with subcortical ischemic stroke. Neurology. 2014;83:398–405. doi: 10.1212/WNL.0000000000000643.
    1. Dávalos A, Toni D, Iweins F, Lesaffre E, Bastianello S, Castillo J. Neurological deterioration in acute ischemic stroke: potential predictors and associated factors in the European cooperative acute stroke study (ECASS) I. Stroke. 1999;30:2631–2636. doi: 10.1161/01.STR.30.12.2631.
    1. Baizabal-Carvallo JF, Alonso-Juarez M, Samson Y. Clinical deterioration following middle cerebral artery hemodynamic changes after intravenous thrombolysis for acute ischemic stroke. J Stroke Cerebrovasc Dis. 2013;23:254–258. doi: 10.1016/j.jstrokecerebrovasdis.2013.01.015.
    1. Lavallée PC, Labreuche J, Faille D, Huisse MG, Nicaise-Roland P, Dehoux M, et al. Circulating markers of endothelial dysfunction and platelet activation in patients with severe symptomatic cerebral small vessel disease. Cerebrovasc Dis. 2013;36:131–138. doi: 10.1159/000353671.
    1. Toghi H, Suzuki H, Tamura K, Kimura B. Platelet volume, aggregation, and adenosine triphosphate release in cerebral thrombosis. Stroke. 1991;22:17–22. doi: 10.1161/01.STR.22.1.17.
    1. Kernan WN, Ovbiagele B, Black HR, Bravata DM, Chimowitz MI, Ezekowitz MD, et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014;45:2160–2236. doi: 10.1161/STR.0000000000000024.
    1. CAPRIE Steering Committee A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) Lancet. 1996;348:1329–1339. doi: 10.1016/S0140-6736(96)09457-3.
    1. Yin T, Miyata T. Pharmacogenomics of clopidogrel: evidence and perspectives. Thromb Res. 2011;128:307–316. doi: 10.1016/j.thromres.2011.04.010.
    1. Rho GJ, Shin WR, Kong TS, Kim MS, Lee CJ, Lee BH. Significance of clopidogrel resistance related to the stent-assisted angioplasty in patients with atherosclerotic cerebrovascular disease. J Korean Neurosurg Soc. 2011;50:40–44. doi: 10.3340/jkns.2011.50.1.40.
    1. Yi X, Lin J, Zhou Q, Wu L, Cheng W, Wang C. Clopidogrel resistance increases rate of recurrent stroke and other vascular events in Chinese population. J Stroke Cerebrovasc Dis. 2016;25:1222–1228. doi: 10.1016/j.jstrokecerebrovasdis.2016.02.013.
    1. Yi X, Lin J, Wang Y, Zhou Q, Wang C, Cheng W, et al. Association of cytochrome P450 genetic variants with Clopidogrel resistance and outcomes in acute ischemic stroke. J Atheroscler Thromb. 2016;23:1188–1200. doi: 10.5551/jat.33290.
    1. Martinez-Quintana E, Tugores A. Clopidogrel: a multifaceted affair. J Clin Pharmacol. 2015;55:1–9. doi: 10.1002/jcph.413.
    1. Simon T, Verstuyft C, Mary-Krause M, Quteineh L, Drouet E, Méneveau N, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med. 2009;360:363–375. doi: 10.1056/NEJMoa0808227.
    1. Yi X, Wang Y, Lin J, Cheng W, Zhou Q, Wang C. Interaction of CYP2C19, P2Y12, and GPIIIa variants associates with efficacy of Clopidogrel and adverse events on patients with ischemic stroke. Clin Appl Thromb Hemost. 2017;23:761–768. doi: 10.1177/1076029616648408.
    1. Pan Y, Chen W, Xu Y, Yi X, Han Y, Yang QW, et al. Genetic polymorphisms and Clopidogrel efficacy for acute ischemic stroke or transient ischemic attack: a systematic review and meta-analysis. Circulation. 2017;135:21–33. doi: 10.1161/CIRCULATIONAHA.116.024913.
    1. Yi X, Lin J, Wang Y, Zhou J, Zhou Q. Interaction among CYP2C8, GPIIIa and P2Y12 variants increase susceptibility to ischemic stroke in Chinese population. Oncotarget. 2017;8:70811–70820.
    1. Yi X, Lin J, Wang Y, Zhou J, Zhou Q, Wang C. Response to clopidogrel is associated with early neurological deterioration after acute ischemic stroke. Oncotarget. 2018;9:19900–19910.
    1. Lin J, Han Z, Wang C, Yi X, Chai Z, Zhou Q, et al. Dual therapy with clopidogrel and aspirin prevents early neurological deterioration in ischemic stroke patients carrying CYP2C19*2 reduced-function alleles. Eur J Clin Pharmacol. 2018;74:1131–1140. doi: 10.1007/s00228-018-2468-7.
    1. Wang S, Zhao H. Sample size needed to detect gene-gene interactions using association designs. Am J Epidemiol. 2003;158:899–914. doi: 10.1093/aje/kwg233.
    1. Lou XY, Chen GB, Yan L, Ma JZ, Zhu J, Elston RC, et al. A generalized combinatorial approach for detecting gene-by-gene and gene-by-environment interactions with application to nicotine dependence. Am J Hum Genet. 2007;80:1125–1137. doi: 10.1086/518312.
    1. Irino T, Watanabe M, Nishide M, Gotoh M, Tsuchiya T. Angiographical analysis of acute cerebral infarction followed by “cascade”-like deterioration of minor neurological deficits. What is progressing stroke? Stroke. 1983;14:363–368. doi: 10.1161/01.STR.14.3.363.
    1. Fateh-Moghadam S, Li Z, Ersel S, Reuter T, Htun P, Plockinger U, et al. Platelet degranulation is associated with progression of intima-media thickness of the common carotid artery in patients with diabetes mellitus type 2. Arterioscler Thromb Vasc Biol. 2005;25:1299–1303. doi: 10.1161/01.ATV.0000165699.41301.c5.
    1. Yi X, Lin J, Wang C, Zhang B, Chi W. A comparative study of dual versus monoantiplatelet therapy in patients with acute large-artery atherosclerosis stroke. J Stroke Cerebrovasc Dis. 2014;23:1975–1981. doi: 10.1016/j.jstrokecerebrovasdis.2014.01.022.
    1. Wang C, Yi X, Zhang B, Liao D, Lin J, Chi L. Clopidogrel plus aspirin prevents early neurologic deterioration and improves 6-month outcome in patients with acute large artery atherosclerosis stroke. Clin Appl Thromb Hemost. 2015;21:453–461. doi: 10.1177/1076029614551823.
    1. Bugnicourt JM, Roussel B, Garcia PY, Canaple S, Lamy C, Godefroy O. Aspirin non-responder status and early neurological deterioration: a prospective study. Clin Neurol Neurosurg. 2011;113:196–201. doi: 10.1016/j.clineuro.2010.11.004.
    1. Wang Y, Wang Y, Zhao X, Liu L, Wang D, Wang C, et al. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med. 2013;369:11–19. doi: 10.1056/NEJMoa1215340.
    1. Mehta SR, Tanguay JF, Eikelboom JW, Jolly SS, Joyner CD, Granger CB, et al. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet. 2010;376:1233–1243. doi: 10.1016/S0140-6736(10)61088-4.
    1. Fontana P, Dupont A, Gandrille S, Bachelot-Loza C, Reny JL, Aiach M, et al. Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects. Circulation. 2003;108:989–995. doi: 10.1161/01.CIR.0000085073.69189.88.
    1. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Alfonso F, Sabaté M, Fernández C, et al. PlA polymorphism and platelet reactivity following clopidogrel loading dose in patients undergoing coronary stent implantation. Blood Coagul Fibrinolysis. 2004;15:89–93. doi: 10.1097/00001721-200401000-00014.
    1. Galic E, Vrbanic L, Kapitanovic S, Catela Ivković T, Petro D, Vuković I. P2RY12 gene polymorphisms and effect of clopidogrel on platelet aggregation. Coll Antropol. 2013;37:491–498.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe